Orbis Research: Global Hemophilia Market

Hemophilia is an inherited or acquired bleeding disorder that prevents blood from clotting. People with hemophilia lack, either partially or completely, an essential clotting factor needed to form stable blood clots. People with hemophilia do not bleed any faster than normal, but they can bleed for a longer time. Hemophilia is quite rare and about 1 in 10,000 people are born with it, around 0.42 million people live with hemophilia. Hemophilia patients need to replace the missing factor through infusions.

Request a sample of this report @ http://www.orbisresearch.com/reports/reportEnquiry/10690

The main treatment is called replacement therapy, in which concentrates of clotting factor VIII (for hemophilia A) or clotting factor IX (for hemophilia B) are injected into a vein. More people suffer with hemophilia A in comparison to hemophilia B and Inhibitors. The US accounts for the major population suffering with hemophilia globally.

The key trends observed in the market include introduction of new products increased competition in rFVIII market and adoption of prophylactic treatment. On the development front, there has been an increase in the launch of new products like next-Generation long-acting Factor VIII and ready-to-use product by Novo Nordisk. But there are certain challenges too which include high risk and cost associated with new drugs, rising cost of hemophilia treatment and low switching rate among patients. The future drivers of the industry are increased rate of diagnosis and treatment, rising male population and global healthcare expense among others.

The report provides a comprehensive study of hemophilia market globally and also provides detailed information for key regional markets. The competition in the global hemophilia market is intense among large players like Baxter International Inc., Novo Nordisk and Pfizer. All these companies have been profiled in the present report highlighting their key financials and business strategies for growth.

By combining SPSS Inc.’s data integration and analysis capabilities with our relevant findings, we have predicted the future growth of the industry. We employed various significant variables that have an impact on this industry and created regression models with SPSS Base to determine the future direction of the industry. Before deploying the regression model, the relationship between several independent or predictor variables and the dependent variable was analyzed using standard SPSS output, including charts, tables and tests.

Purchase a copy of Hemophilia Market visit @ http://www.orbisresearch.com/reports/index/-global-hemophilia-market-report-2015-edition

Table Of Content:

1. Overview

2. Market Analysis

2.1 Global Hemophilia Market
-Market Value
-Market Segmentation

2.2 Hemophilia Market by Segments

2.2.1 Hemophilia A
-Market Value
-Patients Treated
-Regional Breakdown
-Supply/Demand of Factor VIII

2.2.2 Hemophilia B
-Market Value
-Patients Treated

2.2.3 Hemophilia A & B with Inhibitors
-Market Value

2.2.4 Von Willebrand Disease
-Market Value

2.3 Regional Analysis

2.3.1 The US
-Market Size
-Patients Treated
-Hemophilia Prevalence

2.3.2 Australia
-Market Overview
-Market Share

2.3.3 Europe
-Market Size
-Patients Treated

3. Market Dynamics

3.1 Growth Drivers

3.1.1 Increased Rate of Diagnosis and Treatment
3.1.2 Rising Male Population
3.1.3 Rising Global Healthcare Expense
3.1.4 FDA Regulation and Patents

3.2 Key Trends

3.2.1 Introduction of New Products
3.2.2 Increased Competition in rFVIII Market
3.2.3 Adoption of Prophylactic Treatment

3.3 Challenges

3.3.1 High Risk and Cost Associated with New Drugs
3.3.2 Rising Cost of Hemophilia Treatment
3.3.3 Low Switching Rate among Patients

3.4 Significant Developments

3.4.1 Next-Generation Long-Acting Factor VIII in Process
3.4.2 Ready-To -Use Product by Novo Nordisk

4. Competitive Landscape

4.1 Global
-Market Share
-Products in Development

4.2 The US
-Leading Products

5. Company Profiles

5.1 Baxter International Inc.

5.1.1 Business Overview
5.1.2 Financial Overview
5.1.3 Business Strategies
-Advancing Core Portfolio Globally
-Driving Innovation through R&D Pipeline

5.2 Novo Nordisk

5.2.1 Business Overview
5.2.2 Financial Overview
5.2.3 Business Strategies
-Strategic Positioning of Hemophilia Portfolio
-Focused Patient-Centered Strategy

5.3 Pfizer, Inc.

5.3.1 Business Overview
5.3.2 Financial Overview
5.3.3 Business Strategies
-Business Development Initiatives
-Focusing on Research Operations

6. Market Outlook

6.1 Market Forecast
6.2 Forecast Methodology

6.2.1 Dependent and Independent Variables
6.2.2 Correlation Analysis
6.2.3 Regression Analysis

For any enquires before buying, connect with us @ enquiry@orbisresearch.com

About Us:

Orbis Research (orbisresearch.com) is a single point aid for all your market research requirements. We have vast database of reports from the leading publishers and authors across the globe. We specialize in delivering customized reports as per the requirements of our clients. We have complete information about our publishers and hence are sure about the accuracy of the industries and verticals of their specialization. This helps our clients to map their needs and we produce the perfect required market research study for our clients.

Contact Us:

Hector Costello

Senior Manager – Client Engagements

4144N Central Expressway,

Suite 600, Dallas,

Texas - 75204, U.S.A.

Phone No.: +1 (214) 884-6817; +912064101019

Follow Us on LinkedIn: https://www.linkedin.com/company/orbis-research

Follow us on Twitter: https://twitter.com/orbisresearch

Like us on Facebook: https://www.facebook.com/pages/Orbis-Research/820969017982115